ResearchAndMarkets.com has added separate sales forecast and market-size reports for VONJO (pacritinib) and OJJAARA (momelotinib), covering the United States, Germany, France, Italy, Spain, the United Kingdom and Japan through 2034. VONJO is FDA-approved for adults with intermediate- or high-risk primary or secondary myelofibrosis and platelet counts below 50 10^9/L, while OJJAARA is approved for adults with intermediate- or high-risk myelofibrosis with anemia regardless of previous JAK inhibitor treatment. The reports assess clinical performance, commercial uptake, pricing, reimbursement, patents, competition and possible expansion into graft-versus-host disease, VEXAS syndrome, myelodysplastic syndromes and acute myeloid leukemia. VONJO’s PERSIST-2 data showed at least a 35% spleen-volume reduction in 29% of patients with platelet counts below 50 10^9/L versus 3% receiving best available therapy, while OJJAARA’s MOMENTUM study showed transfusion independence in 30% of patients versus 20% with danazol, alongside spleen and symptom improvements. Future performance for both products will depend on clinical evidence, physician adoption, payer access, competitive launches, regulatory developments and potential label expansion.